Results 11 to 20 of about 87,967 (330)
Effect of phosphodiesterase inhibitors in the bladder
Asian Journal of Urology, 2015 Many aging men will experience lower urinary tract symptoms (LUTS). Phosphodiesterase type 5 (PDE5) inhibitors have shown promise in treating LUTS in these patients.
Bilal Chughtai +3 more
doaj +4 more sources
Repurposing Phosphodiesterase-5 inhibitors as chemoadjuvants [PDF]
Frontiers in Pharmacology, 2013 Phosphodiesterase-5 (PDE5) inhibitors have shown a beneficial effect in a variety of clinical conditions, such as benign prostate hyperplasia, pulmonary arterial hypertension, female sexual arousal disorder, overactive bladder, and incontinence, Raynaud's disease, heart failure and stroke among others (Sandner et al., 2007).
Amit K. Tiwari, Zhe-Sheng eChen
doaj +4 more sources
Theophylline and phosphodiesterase inhibitors [PDF]
European Respiratory Journal, 1995 Michel Aubier, Peter J. Barnes
openalex +4 more sources
Phosphodiesterase inhibitors [PDF]
British Journal of Pharmacology, 2006 Phosphodiesterases are a diverse family of enzymes that hydrolyse cyclic nucleotides and thus play a key role in regulating intracellular levels of the second messengers cAMP and cGMP, and hence cell function. Theophylline and papaverine have historically been used therapeutically and are known to be weak inhibitors of PDE, but to what extent this ...
Boswell-Smith, V, Spina, D, Page, C P
openaire +4 more sources
Pulmonary Circulation, 2020 Phosphodiesterase-5 inhibitors are commonly used in pulmonary arterial hypertension but, as suggested by the RESPITE study, phosphodiesterase-5 inhibitor therapy (mono-/combination) does not always have a satisfactory treatment effect.
Clara Hjalmarsson +8 more
doaj +1 more source
PDE5 inhibitor drugs for use in dementia
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2023 Alzheimer's disease and related dementias (ADRD) remain a major health‐care challenge with few licensed medications. Repurposing existing drugs may afford prevention and treatment.
Atticus H. Hainsworth +4 more
doaj +1 more source
Phosphodiesterase Type 5 Inhibitors, Sport and Doping [PDF]
, 2017 Phosphodiesterase type 5 inhibitors (PDE5i) (e.g., sildenafil, tadalafil, vardenafil, and avanafil) are drugs commonly used to treat erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia.
Borrione, Paolo +8 more
core +1 more source
The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review. [PDF]
, 2018 Agents that augment cerebral blood flow (CBF) could be potential treatments for vascular cognitive impairment. Phosphodiesterase-5 inhibitors are vasodilating drugs established in the treatment of erectile dysfunction (ED) and pulmonary hypertension.
Barrick, TR +6 more
core +1 more source
Nonsteroidal anti-inflammatory drugs as potential ecto-nucleotide phosphodiesterase inhibitors
Brazilian Journal of Pharmaceutical Sciences, 2020 Phosphodiesterases (PDE) are group of enzymes which catalyze the hydrolysis of cAMP and cGMP. Since these cyclic phosphate moieties worked as intracellular second messengers in numerous physiological processes, their inhibition can affect normal ...
Shumaila Tasneem +2 more
doaj +1 more source
The low KM-phosphodiesterase inhibitor denbufylline enhances neuronal excitability in guinea pig hippocampus in vitro [PDF]
, 1990 The actions of the phosphodiesterase inhibitor denbufylline on the excitability of hippocampal neurons were investigated by means of extracellular and intracellular recordings.
Alzheimer, Christian +3 more
core +1 more source